Vascular and nerve biomarkers in thigh skin biopsies differentiate painful from painless diabetic peripheral neuropathy
Physicians soon noticed that patients using these medications experienced significant weight loss as a side effect, prompting researchers to investigate their potential for obesity treatment
This helps produce short-chain fatty acids (SCFAs) and eventually stimulates GLP-1 release
Ludvik B, Giorgino F, Jdar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Common GLP-1 receptor agonists include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)